


1615

**TRANSMITTAL LETTER
(General - Patent Pending)**

Docket No.
112703-035



In Re Application Of: Ream et al.

Serial No.
09/286,818

Filing Date
April 6, 1999

Examiner
S. Tran

Group Art Unit
1615

Title:

PHARMACEUTICAL CHEWING GUM FORMULATIONS

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is:

RECEIVED


OCT 04 2000

TECH CENTER 1600/2900

Response to Restriction Requirement (2 pages); and Return Receipt Postcard.

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **02-1818** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.




Signature

Dated: September 27, 2000

**Robert M. Barrett (30,142)
BELL, BOYD & LLOYD LLC
P.O. Box 1135
Chicago, IL 60690-1135
Tel: (312) 807-4204
Fax: (312) 827-1270**

I certify that this document and fee is being deposited on 9/27/00 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Signature of Person Mailing Correspondence

Renee Street

Typed or Printed Name of Person Mailing Correspondence

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Ream et al. ATTY. DOCKET NO.: 112703-035
SERIAL NO.: 09/286,818 GROUP ART UNIT: 1615
FILING DATE: April 6, 1999 EXAMINER: S. Tran
TITLE: "PHARMACEUTICAL CHEWING GUM FORMULATIONS"

Assistant Commissioner for Patents

Washington, D.C. 20231

RECEIVED

OCT 04 2000

RESPONSE TO RESTRICTION REQUIREMENT

TECH CENTER 1600/2500

SIR:

Please enter the following Response to Restriction Requirement in the above-identified patent application.

REMARKS

This Response is submitted in response to the Office Action mailed on August 29, 2000. The Office Action requires Applicants to elect one of two patentably distinct species: A) analgesics, muscle relaxants, antibiotics, antiviral, antihistamine, decongestant, anti-inflammatory, antacid, psychotherapeutic agent, insulin, vitamin, mineral, and cardiovascular agents; and B) stimulants. The Patent Office states that Claims 1 and 14 are generic.

Applicants elect without traverse species group A. Applicants, however, disagree that only Claims 1 and 14 are generic. Regardless, the following claims read on the elected species: Claims 1-12 and 19-22.